

Jeffrey D. Capello Appointed to Flex Pharma's Board of Directors

[Click to Tweet this News](#)

April 6, 2015

Boston, MA – Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Jeffrey D. Capello, Chief Financial Officer of Ortho-Clinical Diagnostics, Inc., has joined its Board of Directors and will serve as Chair of the Audit Committee.

Appointed in 2014, Mr. Capello is the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, which was acquired by The Carlyle Group (NASDAQ: CG) from Johnson & Johnson (NYSE: JNJ), with responsibility for global finance and business development. Prior to his role at Ortho-Clinical Diagnostics, Mr. Capello served as Chief Financial Officer and Executive Vice President of Boston Scientific (NYSE: BSX) from 2010 to 2013. At Boston Scientific, Mr. Capello was responsible for the worldwide management of Boston Scientific's finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc. (NYSE: PKI) from 2006 to 2008. Previously, he served as PerkinElmer's Vice President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at PricewaterhouseCoopers LLP, both in the United States and in the Netherlands. Mr. Capello serves on the Board of Directors of OvaScience, Inc. (NASDAQ: OVAS) and is the Chair of the Audit Committee. Mr. Capello was also a member of the Board of Directors of Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008) and served as the Chair of its Audit Committee. Mr. Capello holds a B.S. degree in business administration from the University of Vermont and an M.B.A. degree from Harvard Business School. Mr. Capello is also a certified public accountant.

"Jeff's financial expertise will be highly valuable to Flex Pharma as we work towards the launch of our consumer product in 2016 and we advance into human proof-of-concept studies in nocturnal leg cramps," commented Christoph Westphal, M.D., Ph.D., Chairman and Chief Executive Officer of Flex Pharma.

Also on the Board of Directors of Flex Pharma are Rod MacKinnon, M.D., Nobel Laureate and scientific co-founder; John Sculley, former Apple CEO and PepsiCo CEO; Peter Barton Hutt, former General Counsel of the U.S. Food and Drug Administration; Marc Kozin, Senior Advisor to L.E.K. Consulting; Stuart Randle, former CEO of GI Dynamics; and Dr. Westphal, Chairman and Chief Executive Officer of Flex Pharma.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success and timing of ongoing and anticipated clinical studies for our current product candidates; and the timing of and our expectations for the launch of our consumer product. Various factors may cause differences between our expectations and actual results as discussed in greater detail under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read Flex Pharma's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to

update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

###

Contact:

Elizabeth Woo

SVP, Investor Relations & Corporate Communications

Flex Pharma, Inc.

irdept@flex-pharma.com

617-874-1829